Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy

What this Trial Is About

Researchers are studying the interaction between blood clotting and inflammation in patients hospitalized with COVID-19, especially those with severe pneumonia. This study aims to better understand how these processes contribute to the risk of blood clots in these patients. The project focuses on patients admitted to Amiens Hospital with COVID-19 infection to analyze their hemostasis and coagulation. The study involves collecting blood samples from patients at admission and weekly during their hospital stay to measure various blood clotting factors such as thrombin time, factor V, factor II, fibrin/fibrinogen degradation products, and antithrombin. Antibodies related to clotting disorders and SARS-CoV-2 viral load and immune response are also assessed at admission and four weeks later. In addition, venous ultrasound scans are performed weekly to check for blood clots until patients are discharged. Participants will undergo regular blood tests and ultrasound exams to monitor their blood clotting and inflammation status. Researchers will track changes in clotting factors and antibody levels over up to six weeks. The study measures include thrombin time, factor V and II concentrations, and fibrin degradation products. These assessments help understand the role of inflammation-induced thrombosis in COVID-19 patients. The total participation time depends on the hospital stay duration, with weekly monitoring until discharge.

Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy